MBA Advisors LLC Buys 932 Shares of Pfizer Inc. $PFE

MBA Advisors LLC lifted its stake in Pfizer Inc. (NYSE:PFE) by 5.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 19,037 shares of the biopharmaceutical company’s stock after acquiring an additional 932 shares during the period. MBA Advisors LLC’s holdings in Pfizer were worth $461,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in PFE. Pacer Advisors Inc. raised its position in shares of Pfizer by 856.8% in the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company’s stock worth $508,164,000 after acquiring an additional 17,957,928 shares in the last quarter. Amundi raised its position in shares of Pfizer by 43.4% in the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock worth $1,265,277,000 after acquiring an additional 15,758,846 shares in the last quarter. Nuveen LLC purchased a new position in Pfizer during the 1st quarter worth $389,861,000. Goldman Sachs Group Inc. grew its stake in Pfizer by 51.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company’s stock worth $670,407,000 after buying an additional 9,041,990 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its stake in Pfizer by 307.5% during the 1st quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company’s stock worth $254,574,000 after buying an additional 7,581,030 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Morgan Stanley boosted their target price on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday. Bank of America boosted their target price on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Finally, Citigroup boosted their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $28.12.

Pfizer Stock Up 0.3%

Pfizer stock opened at $23.84 on Tuesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The business’s 50-day simple moving average is $24.54 and its two-hundred day simple moving average is $24.11. The company has a market cap of $135.54 billion, a PE ratio of 12.68, a PEG ratio of 0.77 and a beta of 0.55. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.